NephCure加速治愈研究所:改善肾病综合征诊疗的多学科联盟
NACI是由NephCure Kidney International与密歇根大学资助的多学科协作组织,包含7个核心模块,旨在改善肾小球疾病患者的治疗选择与结局。其临床试验网络涵盖22个肾病实践站点,截至2017年10月注册患者1054例,诊断包括局灶节段性肾小球硬化、微小病变、膜性肾病、IgA肾病及儿童期起病的肾病综合征等。通过电子健康记录数据提取,高效捕获临床数据并减轻站点负担。
要点
- NACI整合临床试验网络、数据仓库、患者报告结局与终点联盟等7个核心,多维度推进肾小球疾病研究。
- 截至2017年10月,NACI注册研究纳入1054例患者,覆盖多种肾小球疾病诊断。
- 利用电子健康记录数据提取,在减轻站点工作人员负担的同时获取稳健临床数据。
核心结论
- NACI通过联合患者、学术界、产业界及患者倡导社区,致力于以循证支持临床试验设计,改善肾小球疾病患者的结局与治疗。
研究设计与样本
- NACI是由NephCure Kidney International和密歇根大学资助的协作组织,由7个核心组成,包括临床试验网络、数据仓库、患者报告结局与终点联盟等。
- 临床试验网络包含22个社区和医院肾病实践站点,其中14个为仅试验站点;8个站点参与NACI注册研究,截至2017年10月共纳入1054例患者。
主要发现
- 注册患者诊断包括但不限于局灶节段性肾小球硬化、微小病变、膜性肾病、IgA肾病和儿童期起病的肾病综合征。
- 通过电子健康记录数据提取,可高效捕获稳健的临床数据,同时最小化站点网络工作人员的负担。
- 数据仓库包含注册患者的电子健康记录提取数据、患者报告结局开发数据以及已完成的观察性研究和临床试验数据。
- 临床试验咨询团队利用这些数据支持罕见病的试验设计;患者报告结局与终点联盟开发更短期的终点,同时捕获研究干预措施对患者报告的意义。
临床怎么用
- 临床医生可参考NACI的多学科协作模式,利用电子健康记录数据提取优化肾小球疾病的临床数据收集。
- NACI的注册研究和数据仓库可为肾小球疾病临床试验设计提供数据支持,尤其是罕见病领域。
- 关注患者报告结局与短期终点的开发,有助于在临床研究中更好地体现干预措施对患者的意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: NephCure Accelerating Cures Institute (NACI) is a collaborative organization sponsored by NephCure Kidney International and the University of Michigan. The Institute is composed of 7 cores designed to improve treatment options and outcomes for patients with glomerular disease: Clinical Trials Network, Data Warehouse, Patient-Reported Outcomes (PRO) and Endpoints Consortium, Clinical Trials Consulting Team, Quality Initiatives, Education and Engagement, and Data Coordinating Center. METHODS: The Trials Network includes 22 community- and hospital-based nephrology practices, 14 of which are trial-only sites. Eight sites participate in the NACI Registry, and as of October 2017, 1054 patients are enrolled with diagnoses including but not limited to focal segmental glomerulosclerosis, minimal change disease, membranous nephropathy, IgA nephropathy, and childhood-onset nephrotic syndrome. By using electronic health record data extraction, robust and efficient clinical data are captured while minimizing the burden to site-based network staff. RESULTS: The Data Warehouse includes her-extracted data from registry patients, PRO development data, and data from completed observational studies and clinical trials. The Clinical Trial Consulting Team provides support for trial design in rare diseases leveraging these data. The PRO and Endpoints Consortium develops shorter-term endpoints while capturing the patient-reported significance of interventions under study. The Quality Initiatives and Education/Engagement cores elevate the level of care for patients. The Data Coordinating Center manages the analysis and operations of the Institute. CONCLUSION: By engaging with patients, academia, industry, and patient advocate community representatives, including our Patient Advisory Board, NACI strives for better outcomes and treatments using evidence-based support for clinical trial design.
引用
- Gipson DS, Selewski DT, Massengill SF, et al. NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome. Kidney Int Rep. 2017. PMID: 29725648. doi:10.1016/j.ekir.2017.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。